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Chromosomal Localization of Putative
Tumor-Suppressor Genes in Several Human
Cancers
by Jun Yokota,* Takashi Sugimura,* and Masaaki Terada*
Restriction-fragment-length polymorphism analysis was performed on several different types ofhuman
cancers, includingcarcinoma ofthe uterine cervix, neuroblastoma, hepatocellular carcinoma, pheochrom-
ocytoma, stomach cancer, and small-cell lung carcinoma (SCLC), to determine the chromosomal loci of
putative tumor-suppressor genes in each type of tumor because loss of heterozygosity (LOH) is supposed
to unmask the recessive mutation of tumor-suppressor gene in the remaining allele. Chromosomal loci
showing frequent LOH differed among these tumors, suggesting that there are several tumor-suppressor
genes in the human genome and thatcritical genes forthedevelopment ofeach type oftumoraredifferent.
In some cases LOH was observed in the early stage of tumor such as chromosome 3p loss in carcinoma
of the uterine cervix, and in other cases it was observed only in the advanced stage of tumor such as
chromosomes 4 and 16q loss in hepatocellular carcinoma. These results suggestthat there aretwodifferent
types of tumor-suppressor genes: one is the gene whose inactivation is responsible for malignant trans-
formation ofa normal cell and the other is the gene whose inactivation is responsible for the progression
of a tumor cell. In SCLC, LOH at three different chromosomal loci, 3p, 13q, and 17p, was simultaneously
observed in nearly 100% of tumors. It was observed even in stage I tumors and an untreated tumor, and
it occurred prior to N-myc amplification. These results may imply that at least six genetic alterations are
necessary to convert a normal cell into a fully malignant cancer cell in SCLC.
Introduction
Tumor-suppressor genes can be inactivated by either
mutation or loss, and loss of heterozygosity (LOH) is
believed to be a critical chromosomal mechanism to lose
one ofthe allelic genes. Recent molecular genetic stud-
ies have shown that LOH at specific chromosomal loci
occurs very frequently in certain types of human tu-
mors, suggesting that inactivation oftumor-suppressor
genes is involved in the development of a wide variety
of human cancers. Molecular analysis of genetic alter-
ations with reference to the clinical and biological be-
havior of cancer cells will give us valuable information
for understanding the molecular mechanisms involved
in human carcinogenesis. We have performed a restric-
tion-fragment-length polymorphism (RFLP) analysis
for several different types of human cancers to deter-
minethechromosomallociofputative tumor-suppressor
genes in each type of tumor. LOH at specific chromo-
somal loci was detected frequently and specifically in
each type of cancer. The results of our RFLP analysis
will be summarized and described here with specific
emphasis on those ofsmall-cell lung carcinoma (SCLC).
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Loss of Heterozygosity in Several
Human Cancers
An RFLP analysis was performed for several differ-
ent types ofhuman cancers, including carcinoma ofthe
uterine cervix, neuroblastoma, hepatocellular carci-
noma, pheochromocytoma, stomach cancer, and SCLC.
LOH was observed at specific loci with high frequency
in these cancers, and the loci showing frequent allele
loss differed in each type ofcancer (Table 1).
In carcinoma ofthe uterine cervix, LOH at the D3S2
locus on chromosome 3p was observed in all nine pa-
tients who could be evaluated (1). Human papilloma
virus type 16 and 18 were present in 7 and 3 of 18
tumors, respectively, while no amplification of 13 on-
cogenes, including c-myc and c-H-ras, was detected in
these tumors. These results suggest that recessive ge-
netic changes on chromosome 3p are one ofthe impor-
tant genetic alterations for the development of carci-
noma of the uterine cervix. Since this locus is also lost
commonly in lung cancer and in renal cell carcinoma, it
is possible that these three different types of adult tu-
mors result from mutations of the same tumor-sup-
pressor gene on chromosome 3p.
In neuroblastoma, the incidence of LOH was high at
the D14S1 locus on chromosome 14q, being detected in
6 of 12 patients (50%) (2). LOH on 14q was detected inYOKOTA ET AL.
Table 1. Loss of heterozygosity in human cancers.
Site of
Type of tumor allele loss Incidence (%) Reference
Small-cell lung 3p 15/15 (100%) (10,11)
carcinoma
13q 15/16 (94%)
17p 16/16 (100%)
Carcinoma of the 3p 9/9 (100%) (1)
uterine cervix
Neuroblastoma lp 2/9 (22%) (2)
14q 6/12 (50%)
Hepatocellular 4 8/16 (50%) (3)
carcinoma
16q 8/14 (57%)
Pheochromocytoma lp 3/4 (75%) (4)
lip 3/5 (60%)
Stomach cancer Nonspecific - (5)
and infrequent
two stage-I patients, who had received no chemother-
apy or radiotherapy before the surgical removal ofthe
tumors. In spite of the cytogenetic finding suggesting
high frequency ofchromosome lp deletion, LOH at the
MYCL locus on lp32 was detected only in two of nine
patients (22%). These results indicate that the tumor-
suppressor geneforneuroblastomaislocated onthelong
arm of chromosome 14, and inactivation of this gene is
critical for the malignant transformation of cells. The
results also indicate that chromosome lp deletion, as
well as N-myc amplification, may be a secondary event
occurring during the progression of neuroblastoma.
In hepatocellular carcinoma, LOH at the HP locus on
16q22 and at the MT2P1 on 4pll-q21 was detected in
57% (8/14) and 50% (8/16) of the tumors, respectively
(3). These losses were predominantly detected in the
advanced stage of tumors and seem to be common in
both hepatocellular carcinogenesis associated with hep-
atitis B virus infection and with non-A non-B hepatitis.
On the other hand, incidence of LOH was low at other
chromosomal loci, e.g., chromosomes lp, 3p, llp, 13q,
or 17p, where LOH occurs frequently in other types of
cancers such as carcinomas ofthe lung, kidney, bladder,
and uterine cervix. Since there is no report showing
frequent LOH on chromosome 16 or 4 in cancers other
than hepatocellular carcinoma, recessive genetic
changes involving sequences on these chromosomes
seemtobe specifically associated withdevelopment and/
or progression of hepatocellular carcinoma.
We have performed an RFLP analysis for several
other types of human tumors. One interesting obser-
vationisthat LOH wasdetected evenin abenigntumor.
In pheochromocytoma, LOH on chromosomes lp and
llp was detected in 75% (3 of4 patients) and 60% (3 of
5 patients), respectively (4). In spite of our effort to
determine the chromosomal loci ofputative tumor-sup-
pressor genes for stomach cancers by a similar ap-
proach, common chromosomal loci showing frequent
LOH have not yet been determined in stomach cancer
(5).
Loss of Heterozygosity on
Chromosomes 3p, 13q, and 17p in
Small-Cell Lung Carcinoma
In SCLC, two different types of genetic alterations
have been reported: one is the deletion of chromosome
3 (6,7) and the other is the amplification ofmyc family
oncogenes (8,9). We performed an RFLP analysis for
16 fresh tumors and 9 cell lines derived from SCLCs
(10,11). As suggested by the cytogenetic studies, LOH
on the shortarm ofchromosome 3was observedin 100%
(15/15) of the informative cases. However, an RFLP
analysis revealed additional chromosomal changes,
namely, the frequent occurrence of LOH on chromo-
somes 13q and 17p. LOH at chromosome 13q loci was
observed in 15of16cases (94%) andthatonchromosome
17p loci occurred in all 16 cases analyzed (100%). The
common regions of LOH on chromosomes 3, 13, and 17
reside between D3S2 (3pl4-p2l) and ErbA (3p22-
p24.1), between D13S1 (13q12) and D13S2 (13q22), and
distal to MYH2 (17pl3.1), respectively. LOH on these
chromosomes wassimultaneously observedinfourcases
of stage I tumors and one case of an untreated tumor,
and it occurred prior to N-myc amplification in the case
of a stage IV tumor. These results suggest that LOH
on chromosomes 3p, 13q, and 17p occursrelatively early
in the development of SCLCs and may be critical for
the genesis ofthe tumor rather than being a secondary
event that takes place during the progression of the
tumor, such as N-myc amplification.
LOH on chromosome3pwasalsofrequentlyobserved
in carcinoma of the uterine cervix (1), as described
above, and inrenal cellcarcinoma(12). Thus, itis highly
possible that inactivation ofthe same tumor-suppressor
gene isinvolved inthedevelopment ofthesethree types
oftumors. It is also possible that three different genes
for each type of tumor are located on the same region
ofchromosome 3p. The commonregionofLOH forchro-
mosome 13q in SCLC contains the Rb locus at 13q14,
reminiscent of retinoblastoma. We and others previ-
ously described abnormal transcripts and the absence
ofnormal Rb protein in SCLC, suggesting that the re-
maining allele of the Rb gene is inactivated in these
tumors (13,14). Similar abnormalities of the Rb gene
have been observed in osteosarcoma and breast carci-
noma, in which the frequent occurrence ofLOH on 13q
has also been reported (15,16). These findings strongly
suggest that complete inactivation of the Rb gene is
frequently the net result of LOH on chromosome 13q
in several types of human tumors. Frequent LOH on
the short arm of chromosome 17 has been reported in
colorectal carcinoma, osteosarcoma, and breast carci-
noma, and the p53 gene is supposed to be atarget gene
on this chromosome in these cancers (15,17). These re-
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sults strongly suggested that at least three different
tumor-suppressor genes are involved in the develop-
ment of SCLC and may imply that at least six genetic
alterations are necessary to convert a normal cell into
a fully malignant cancer cell in the case of SCLC.
Two Different Types of Tumor-
Suppressor Genes
In summary, it is concluded that chromosomal loci
showingfrequentLOHdifferamongeachtypeoftumor.
This result suggests that there are many different tu-
mor-suppressor genes in the human genome that are
located on several different chromosomes and that crit-
ical genes for each type of tumor are different among
these tumors. In some cases LOH was detected even
in the early stage oftumor, and in othercases LOH was
observed only in the advanced stage of tumor. There-
fore, we can propose that there are two different types
of tumor-suppressor genes in the human genome. One
is the tumor-suppressor genes whose inactivation is re-
sponsible for malignant formation of normal cells, and
the other is the tumor-suppressor genes whose inacti-
vation is responsible for progression oftumor cells. Fu-
ture studies should focus on the cloning ofcritical genes
from the chromosomal regions showing LOH in tumors.
Characterization of these genes will provide us much
useful information for understanding the biological role
of LOH in tumor development.
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